Comparing two types of minimally invasive surgeries for stomach cancer

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

This study is testing which of two types of minimally invasive surgeries for stomach cancer helps patients recover better and feel good after the operation.

Quick facts

• Study type: Observational
• Enrollment: 10 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Memorial Sloan Kettering Cancer Center (other)
• Locations: 8 sites (Basking Ridge, New Jersey and 7 other locations)
• Trial ID: NCT06243757 on ClinicalTrials.gov

What this trial studies

This study observes patients diagnosed with gastroesophageal junction adenocarcinoma who are scheduled to undergo either minimally invasive proximal gastrectomy (MIPG) or minimally invasive total gastrectomy (MITG) as part of their routine care. Participants will complete a questionnaire one month prior to surgery and then at one, three, six, and twelve months post-surgery to assess outcomes and recovery. The goal is to gather data on the effectiveness and recovery experiences associated with each surgical approach.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with a biopsy-confirmed diagnosis of non-metastatic gastric or gastroesophageal junction adenocarcinoma scheduled for surgery.

Not a fit: Patients with known malabsorption syndromes, narcotic dependence, or those unable to comply with study procedures may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could help determine which surgical method offers better outcomes for patients with gastric and gastroesophageal junction cancers.

How similar studies have performed: Other studies have explored minimally invasive surgical techniques for gastric cancer, showing promising results, but this specific comparison is novel.

Eligibility criteria

Inclusion Criteria:

* Able to speak and read English, Spanish, Japanese or Korean
* Patients with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention
* Age ≥ 18

Exclusion Criteria:

* Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract
* Patients with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent
* Subjects deemed unable to comply with study and/or follow-up procedures, at investigators' discretion
* Patients who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

Where this trial is running

Basking Ridge, New Jersey and 7 other locations

• Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey, United States (RECRUITING)
• Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey, United States (RECRUITING)
• Memorial Sloan Kettering Bergen (All protocol activities) — Montvale, New Jersey, United States (RECRUITING)
• Memorial Sloan Kettering Commack (All Protocol Activities) — Commack, New York, United States (RECRUITING)
• Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York, United States (RECRUITING)
• Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States (RECRUITING)
• Memorial Sloan Kettering Nassau (Limited Protocol Activites) — Rockville Centre, New York, United States (RECRUITING)
• MD Anderson Cancer Center (Data Analysis Only) — Houston, Texas, United States (RECRUITING)

Study contacts

• Principal investigator: Vivian Strong, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Vivian Strong, MD

Conditions: Gastric Cancer, GastroEsophageal Cancer, Gastroesophageal Junction Adenocarcinoma, gastric cancer, non-metastatic gastric cancer, gastroesophageal cancer, GEJ adenocarcinoma, MIPG